Key Highlights
- Christian Howell appointed CEO, succeeding Brent Vaughan
- Focus on commercialization of Alzheimer’s therapy, Spectris™
- Over 20 years of expertise in medical devices and healthcare innovation
Source: Business Wire
Notable Quotes
- “Christian is an exceptional strategic leader with a proven track record in medical device launches, and I look forward to working closely with him as we position Cognito for this next phase of growth.” — Gerald Chan, ScD., Founder of Morningside and Chairman of the Board at Cognito Therapeutics
- “I am honored to take on the role of CEO at Cognito, a company that is at the forefront of innovation in the treatment of neurodegenerative diseases.” — Christian Howell, CEO at Cognito Therapeutics
- “Christian’s leadership at Cognito has fostered a culture of excellence, collaboration, and continuous improvement across the entire organization.” — Dr. Rick Kuntz, Board Member at Cognito Therapeutics
SoHC's Take
Christian Howell’s appointment as CEO of Cognito Therapeutics signals a strategic shift towards the commercialization phase of Spectris™, their innovative Alzheimer’s therapy. With Howell’s extensive background in medical devices and commercialization, Cognito is well-positioned to advance its mission of providing transformative therapies for neurodegenerative diseases. His leadership will be pivotal as the company approaches critical milestones, including the completion of the HOPE pivotal study. This change marks a significant moment in the company’s evolution, setting the stage for further growth and impact in the neurotechnology space.
